The poster will feature Rakuten Medical's ongoing global Phase 3 clinical trial evaluating ASP-1929 photoimmunotherapy in combination with pembrolizumab (anti-PD-1) as a first-line therapy for ...

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing ...

The STAR-101 trial is a first-in-human, multicenter, open-label, Phase 1 dose-escalation study designed to evaluate the safety, feasibility, and preliminary efficacy of SynKIR-110 in patients with ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters ...

Margrit Wiesendanger, MD, PhD, explores lupus symptoms, diagnosis challenges, and the importance of early detection to prevent inflammation-related damage.

were selected for a poster presentation at the European Hematology Association (EHA) 2025 Congress, taking place June 12–15 in Milan, Italy. The presentation will highlight emerging safety ...

SAN DIEGO, April 29, 2025 /PRNewswire/ -- NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor ...

("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in ...

The poster, titled “Outer Retina-Choroid en ... Ophthalmology of MERIT. About the Presentation: • Title: “Outer Retina-Choroid en face Image, ORC™: Characterization of A Novel Morphologic ...